Association between psoriasis and lung cancer: two-sample Mendelian randomization analyses

BMC Pulmonary Medicine

Table 1 Mendelian randomization analyses between psoriasis and lung cancer

Psoriasis	Lung cancer	No. of SNP	Mean F-statistics	Heterogeneity test^a		Horizontal pleiotropy^b			OR (95% CI)^c	Statistical power for detecting OR in 0.95–1.05	Statistical power for detecting OR < 0.9 or > 1.1
Psoriasis	Lung cancer	No. of SNP	Mean F-statistics	Q-statistics	P value	Egger-intercept	se	P value	OR (95% CI)^c	Statistical power for detecting OR in 0.95–1.05	Statistical power for detecting OR < 0.9 or > 1.1
Tsoi LC	LUCA	55	444.3	93.9	< 0.001	−0.0048	0.0116	0.682	1.00 (0.94–1.07)	0.59	0.99
	LUSC	55	444.3	65.8	0.014	−0.0058	0.0152	0.705	1.00 (0.92–1.09)	0.28	0.77
	LUAD	55	444.3	88.4	< 0.001	−0.0018	0.0173	0.918	0.99 (0.90–1.09)	0.28	0.79
FinnGen	LUCA	10	220.0	17.2	0.046	0.0051	0.0330	0.881	1.01 (0.91–1.13)	0.25	0.70
	LUSC	10	220.0	13.4	0.143	0.0302	0.0424	0.496	1.02 (0.88–1.18)	0.13	0.37
	LUAD	10	220.0	21.8	0.009	−0.0701	0.0531	0.223	0.93 (0.77–1.13)	0.13	0.38

^a results were derived from IVW-test
^b results were derived from MR-Egger regression
^c results were derived from IVW-MRE models
LUCA lung cancer; LUSC lung squamous cell carcinoma; LUAD lung adenocarcinoma
se standard error; OR odds ratio; CI confidence interval

ISSN: 1471-2466